Cypher class action suit?
This article was originally published in The Gray Sheet
Kenneth B. Moll & Associates will decide by year-end whether to pursue a class action suit against Johnson & Johnson/Cordis for deaths related to implantation of its sirolimus-eluting stent. Moll currently is conducting an investigation of Cypher patient data FDA released in October that estimated a 0.01% worldwide mortality rate for the device (1"The Gray Sheet" Nov. 3, 2003, p. 4). In June, the Chicago law firm brought a class action suit against Guidant because of deaths related to its Ancure AAA system; the suit is currently in discovery...
You may also be interested in...
FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.